Suven Pharmaceuticals Limited Total Liabilities
Suven Pharmaceuticals Limited total liabilities. Based on the latest financial reports, Suven Pharmaceuticals Limited (SUVENPHAR) has total liabilities worth Rs11.91 Billion INR (≈ $128.81 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Suven Pharmaceuticals Limited liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Suven Pharmaceuticals Limited (2019–2025)
Total liabilities of Suven Pharmaceuticals Limited from 2019 to 2025. This chart illustrates how Suven Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data.
Suven Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Suven Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Texas Capital Bancshares, Inc.
NASDAQ:TCBI
|
USA | $29.88 Billion |
|
Silgan Holdings Inc
NYSE:SLGN
|
USA | $7.22 Billion |
|
Next Vision Stabilized Systems
TA:NXSN
|
Israel | ILA28.00 Million |
|
KONINKLIJKE VOP.UNSP.ADR
F:VPK
|
Germany | €3.54 Billion |
|
Novanta Inc
F:1GSN
|
Germany | €704.34 Million |
|
Kilroy Realty Corp
NYSE:KRC
|
USA | $5.18 Billion |
|
Union Bank of Taiwan Pref
TW:2838A
|
Taiwan | NT$980.49 Billion |
|
Mega Or
TA:MGOR
|
Israel | ILA7.50 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Suven Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Suven Pharmaceuticals Limited.
Liquidity & Leverage Metrics
Suven Pharmaceuticals Limited Total Liabilities Ratios Explained
Suven Pharmaceuticals Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Suven Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Suven Pharmaceuticals Limited (2019–2025)
The table below shows the annual total liabilities of Suven Pharmaceuticals Limited from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs11.91 Billion ≈ $128.81 Million |
+485.53% |
| 2024-03-31 | Rs2.03 Billion ≈ $22.00 Million |
-11.77% |
| 2023-03-31 | Rs2.31 Billion ≈ $24.93 Million |
-23.76% |
| 2022-03-31 | Rs3.02 Billion ≈ $32.70 Million |
+2.98% |
| 2021-03-31 | Rs2.94 Billion ≈ $31.76 Million |
-10.48% |
| 2020-03-31 | Rs3.28 Billion ≈ $35.48 Million |
+70.21% |
| 2019-03-31 | Rs1.93 Billion ≈ $20.84 Million |
-- |
About Suven Pharmaceuticals Limited
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research servic… Read more